Ionela I.
- Country
- Romania
- Department
- Pneumologie
Research Overview
- Therapeutic Equivalence of CHF5993 Combination Therapy Using HFA-152a Versus HFA-134a in Adults With Mild to Moderate Asthma
- Efficacy and Safety of Early Depemokimab Initiation as Add-on Therapy in Patients with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation
- Evaluation of Budesonide, Glycopyrronium Bromide, and Formoterol Fumarate on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease Patients
Data & Insights
Has run more than one trial at 203 of 557 partner sites.
Specializations
Respiratory Medicine
The investigator specializes in treating chronic obstructive pulmonary disease (COPD), with particular focus on advanced therapeutic interventions and innovative treatment approaches.
- Triple therapy optimization
- Lung function improvement
- COPD exacerbation management
Their research extends to exploring combination therapies using pressurized metered dose inhalers and dry powder inhalers.
Therapeutic Innovation
The investigator focuses on evaluating novel therapeutic combinations for respiratory conditions, particularly examining add-on treatments to established maintenance therapies.
- Combination therapy assessment
- Long-term treatment efficacy
- Treatment tolerability studies
Their work encompasses the evaluation of various dosing strategies and delivery systems for respiratory medications.
Clinical Conditions
The investigator's expertise includes treating patients with chronic bronchitis and associated respiratory conditions, focusing on comprehensive disease management approaches.
- Pulmonary function assessment
- Bronchial condition management
- Respiratory symptom control
Their clinical focus includes both acute and maintenance treatment strategies for chronic respiratory conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.